Cytokinetics (CYTK) Projected to Release Quarterly Earnings on Thursday

Cytokinetics (NASDAQ:CYTK) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($1.63) per share and revenue of $17.5880 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million for the quarter, compared to analysts’ expectations of $8.52 million. The company’s revenue for the quarter was up 1112.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.36) EPS. On average, analysts expect Cytokinetics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Trading Up 2.8%

NASDAQ:CYTK opened at $78.61 on Wednesday. The business’s 50-day moving average is $78.78 and its 200 day moving average is $70.62. Cytokinetics has a 12 month low of $32.89 and a 12 month high of $88.31. The company has a market capitalization of $9.78 billion, a P/E ratio of -11.49 and a beta of 0.38.

Insider Transactions at Cytokinetics

In related news, Director B Lynne Parshall sold 5,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $74.08, for a total value of $370,400.00. Following the completion of the sale, the director directly owned 15,784 shares in the company, valued at $1,169,278.72. This trade represents a 24.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the transaction, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at $32,085,323.60. The trade was a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 115,179 shares of company stock worth $9,126,054. 2.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in Cytokinetics during the 4th quarter valued at about $27,000. Kestra Advisory Services LLC bought a new position in Cytokinetics during the 4th quarter valued at about $29,000. Quarry LP purchased a new stake in Cytokinetics in the 3rd quarter worth about $30,000. Finally, Advisory Services Network LLC purchased a new stake in Cytokinetics in the 3rd quarter worth about $32,000.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CYTK shares. Wall Street Zen raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC reiterated a “buy” rating and set a $102.00 target price on shares of Cytokinetics in a research report on Wednesday, June 17th. JPMorgan Chase & Co. raised their target price on shares of Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. HC Wainwright boosted their price target on shares of Cytokinetics from $136.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company upped their price target on shares of Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.90.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.